VIP (Vasoactive Intestinal Peptide): Research Overview

Key takeaways

• VIP is a 28-amino-acid neuropeptide that acts through two main receptors, VPAC1 and VPAC2, and is involved in immune, gut, lung, brain, and metabolic signaling.
• Research links VIP to anti-inflammatory effects, including lower pro-inflammatory cytokine signaling and higher anti-inflammatory signaling in several models.
• In animal and cell studies, blocking VIP signaling has improved anti-tumor immune responses, while VIP itself has shown protective effects in inflammation models such as arthritis.
• VIP also appears in glucose homeostasis research, where it can stimulate glucose-dependent insulin secretion and support beta-cell proliferation.

Vasoactive Intestinal Peptide, or VIP, is a small signaling molecule with a wide reach. It is a 28-amino-acid neuropeptide that appears in the nervous system, the gut, the lungs, the immune system, and the pancreas. Across the sources reviewed here, VIP is described as a pleiotropic regulator. That means it can influence more than one process at a time, including inflammation, smooth muscle tone, circadian timing, immune cell behavior, and insulin release.

That broad biology is why VIP keeps showing up in different research settings. Some studies focus on its anti-inflammatory effects. Others study its role in glucose regulation. Still others look at what happens when the VIP pathway is blocked. Taken together, the evidence paints a clear picture: VIP is not a single-purpose peptide. It is a signaling node that helps coordinate several systems at once.

What VIP is and where it acts

VIP is a naturally occurring peptide first identified in the early 1970s. One review describes it as a systems-level coordinator rather than a signal that acts on one organ alone. Another source notes that it belongs to the glucagon/secretin superfamily and is produced by neurons throughout the enteric nervous system, the central and peripheral nervous systems, and the lungs.

Two main receptors

VIP works mainly through two G-protein-coupled receptors: VPAC1 and VPAC2. These receptors are widely expressed across tissues, including the hypothalamus, lung, small intestine, immune cells, pituitary gland, and vascular smooth muscle. That receptor spread helps explain why VIP can influence so many systems at once.

In the immune system, VIP binding to VPAC1 and VPAC2 has been linked to lower NF-kB activation and reduced production of inflammatory markers such as IL-6, TNF-alpha, IL-12, and MMP-9, with increased IL-10 and TGF-beta1 signaling. In the lung, it has been described as the primary endogenous bronchodilator and pulmonary vasodilator. In the hypothalamus, VIP from suprachiasmatic nucleus neurons helps regulate circadian rhythm entrainment and normal sleep-wake cycling.

A peptide with broad tissue coverage

Because VIP is produced in several tissues and acts on receptors in many more, it is often described as a bridge between the nervous, immune, gut, and endocrine systems. That makes it relevant to topics as different as gut integrity, airway tone, immune tolerance, and hormone release.

Immune regulation and inflammation

The strongest theme across the research is VIP’s role in immune balance. Several sources describe VIP as an anti-inflammatory neuropeptide with regulatory effects on T cells, macrophages, and dendritic cells. In one review, VIP is said to suppress pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-12, while promoting anti-inflammatory cytokines such as IL-10 and increasing regulatory T-cell activity.

Evidence from arthritis models

One Johns Hopkins summary of an experimental arthritis study reported that VIP treatment delayed disease onset, lowered incidence, and reduced severity in a mouse model of collagen-induced arthritis. The same summary described histologic improvements, including less inflammatory infiltrate, pannus formation, cartilage destruction, and bone erosion. It also noted changes in immune signaling: lower Th1 cytokine production, higher Th2 cytokine production, suppression of inflammatory cytokines, and increases in IL-10 and IL-1 receptor antagonist.

These findings matter because they show a pattern repeated in multiple VIP studies: the peptide does not simply suppress immune activity. It appears to shift immune responses toward a less inflammatory state.

Blocking VIP can also be informative

Some of the most useful evidence comes from studies that block the VIP pathway. In a murine leukemia model, a VIP antagonist called VIPhyb enhanced T-cell-dependent anti-leukemia responses. The study reported reduced tumor burden and improved survival, with 30-50% survival in treated mice versus 0-20% in vehicle controls. T cells from treated mice expressed lower PD-1 and secreted more IFN-gamma. T cells from survivors also protected against C1498 leukemia after adoptive transfer.

A later study went further and identified more potent VIP receptor antagonists, including ANT308 and ANT195. In mice engrafted with C1498 leukemia, daily subcutaneous injections of VIP receptor antagonist peptides induced anti-leukemia responses. The study reported that predicted receptor binding correlated positively with T-cell proliferation and anti-leukemia activity. ANT308 also decreased CREB phosphorylation and stimulated granzyme B and perforin expression in CD8+ T cells from AML patients.

These results do not mean VIP is “good” or “bad.” They show that the pathway is biologically active in both immune suppression and immune activation, depending on context. That is one reason VIP remains a research target in both inflammatory disease and cancer immunology.

Gut, lung, and brain signaling

VIP has been described as a key part of the neuro-immune-gut axis. In the gut, it is tied to epithelial integrity and immune tolerance. In the lungs, it is linked to bronchodilation and pulmonary vascular tone. In the brain, it participates in circadian regulation through the suprachiasmatic nucleus.

Gut and epithelial function

One source frames VIP as part of a broader network that supports gut integrity and helps coordinate responses to stress, inflammation, and injury. The same source links impaired VIP signaling with chronic inflammatory illness, gut permeability, immune dysregulation, and neurologic symptoms. Those are associations, not proof of causation, but they reflect why VIP gets attention in integrative and functional medicine discussions.

Lung effects

The lamkinclinic reference describes VIP as the primary endogenous bronchodilator and pulmonary vasodilator in the lungs. It also states that VIP-deficient states are associated with pulmonary arterial hypertension and airway hyperresponsiveness. Those claims fit with VIP’s known role in smooth muscle relaxation and vascular signaling.

Brain and circadian timing

In the suprachiasmatic nucleus, VIP increases neuronal firing. One study reported that application of 1 μM VIP produced a significant increase in the firing rate of dorsal SCN neurons, with the effect lasting after washout and returning to control levels within 4-6 hours. A lower concentration, 0.1 μM, did not change the firing rate. This matters because it shows that VIP is not only a chemical messenger in immune tissue; it is also an active signal in the brain’s clock network.

That is one reason VIP is described as chronobiotic in some clinical reference material. It is also why the peptide is often discussed in relation to sleep-wake regulation, even if the research base there is still limited compared with its immune and endocrine literature.

Glucose homeostasis and beta-cell biology

VIP also appears in metabolic research. A 2022 review in Frontiers in Endocrinology described VIP as a peptide that can stimulate glucose-dependent insulin secretion, particularly through VPAC2 receptors. The same review stated that VIP promotes islet beta-cell proliferation through the forkhead box M1 pathway, though it also noted that the detailed molecular mechanism remains to be studied.

That same review framed this work in the context of type 2 diabetes, a condition with rising global prevalence. It cited an estimated 537 million people with diabetes worldwide in 2021, with type 2 diabetes making up about 90% of cases. The review’s main point is narrow and important: VIP signaling may help support glucose homeostasis without triggering hypoglycemia in the way some glucose-lowering therapies can.

There is a practical limitation, though. The review also states that the clinical application of VIP is limited by its short half-life and wide distribution in the body. That is why researchers have explored VPAC2-selective agonists as a way to keep the useful parts of the signal while improving specificity.

What the evidence does and does not show

VIP has a strong and interesting research profile, but the current evidence is uneven. Much of what is available comes from animal models, cell studies, and review articles. That makes the findings biologically meaningful, but not ready to be treated as direct proof of clinical benefit in humans for any specific condition.

What is supported

The sources support several points consistently. VIP is a 28-amino-acid neuropeptide. It signals through VPAC1 and VPAC2. It has anti-inflammatory effects in multiple models. It can influence T-cell activity, cytokine patterns, smooth muscle tone, circadian signaling, and glucose-dependent insulin secretion. In leukemia models, blocking VIP signaling has improved anti-tumor immune responses. In arthritis models, giving VIP has reduced inflammatory damage.

What remains uncertain

The sources also leave important gaps. The Frontiers review says the specific molecular mechanism for beta-cell proliferation remains to be studied. The cancer work is promising, but it is still preclinical. The inflammation literature points in more than one direction because context matters: in some settings, VIP may be useful because it calms inflammation; in others, blocking the pathway may help by removing immune suppression.

That context dependence is the main caution for reading VIP research. It is not a simple “stimulate” or “block” target. It is a regulatory system with different effects in different tissues and disease models.

How researchers talk about VIP now

VIP is often discussed alongside other peptides that shape immune and neuroendocrine signaling. In peptide research circles, it sits near molecules such as LL37, GHK-Cu, and oxytocin when the topic is signaling, tissue communication, and human physiology. But VIP has a distinct profile because it touches so many systems at once.

That broad profile is also why it appears in both “supportive” and “blocking” strategies in the literature. On one side, it may help explain why some inflammatory pathways quiet down. On the other, the same pathway may be a target to block when immune activity needs to increase, such as in leukemia models.

For researchers, that means VIP should be treated as a context-dependent signaling molecule, not as a one-note peptide. Any serious reading of the literature has to ask three questions: which tissue, which receptor, and which disease model?

FAQ

What is VIP?

VIP stands for Vasoactive Intestinal Peptide. It is a 28-amino-acid neuropeptide that acts through the VPAC1 and VPAC2 receptors and helps regulate immune, gut, lung, brain, and metabolic signaling.

Why is VIP called a regulatory peptide?

Because it affects several systems at once. The sources describe it as influencing inflammation, smooth muscle tone, circadian timing, epithelial integrity, and glucose-dependent insulin secretion.

Does VIP reduce inflammation?

Yes, several sources describe anti-inflammatory effects. Reported changes include lower TNF-alpha, IL-6, IL-12, and NF-kB signaling, along with higher IL-10 and TGF-beta1 signaling. Animal arthritis studies also showed reduced inflammatory damage.

Why would researchers block VIP if it has helpful effects?

Because VIP can also suppress anti-tumor immune responses in some settings. In leukemia models, blocking VIP improved T-cell activity, lowered PD-1, increased IFN-gamma, and improved survival in mice.

What is the main limit of the current VIP evidence?

Most of the evidence comes from preclinical studies and reviews, not large human trials. The sources also note that VIP has a short half-life and broad distribution, which makes translation into therapies more difficult.